Pharmadrug
Holding Companies & Conglomerates · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2905-77 King St. West, Toronto, Ontario,...Website
www.pharmadrug.caRevenue
<$5 MillionStock Symbol
PHRX.CNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
2
2
1
1
About Pharmadrug
PharmaDrug owns 51% of Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. PharmaDrug also owns 100% of SecureDose Synthetics Inc. ("SecureDose"), a pharmaceutical research and development company focused on the development of synthetic formulations of currently existing drugs for potential commercialization and distribution. Our Growth StrategyExplore more
Pharmadrug Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pharmadrug your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Pharmadrug launches new products
Check if Pharmadrug has recently received funding, and reach out quickly before it becomes old news!
Pharmadrug, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Pharmadrug had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Pharmadrug has new funding data
Earning: See what the market has to say on Pharmadrug recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Pharmadrug
Check out if Pharmadrug is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Pharmadrug
Compare insights from companies similar to Pharmadrug, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pharmadrug is experiencing very low activity levels compared to other companies in the Holding Companies & Conglomerates sector.
What does this means?
Pharmadrug is drawing exceptional interest within the Holding Companies & Conglomerates industry, suggesting notable developments or strong market momentum, learn more about Pharmadrug.
Pharmadrug Tech Stack
A closer look at the technologies used by Pharmadrug
See more technologies
Pharmadrug News & Media
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
Toronto, Ontario--(Newsfile Corp. - June 16, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a...PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.
Toronto, Ontario--(Newsfile Corp. - July 18, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it has reached an agreement yesterday with PharmaTher Inc. ("PharmaTher"), a wholly-owned subsidiary of PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF), pursuant to which PharmaTher will subscribe for 144,117,647 common shares of PharmaDrug's subsidiary Sairiyo Therapeutics Inc. ("Sairiyo") for $300,000. Following the issuance, PharmaTher will.PharmaDrug Announces Termination of General Security Agreement and Issuance of Common Shares
Toronto, Ontario--(Newsfile Corp. - July 5, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it has reached an agreement with the holders of $650,000 principal amount of the Company's convertible debentures to terminate a general security agreement granted by the Company's wholly-owned subsidiary Sairiyo Therapeutics Inc. ("Sairiyo"). As consideration for agreeing to terminate the general security agreement the Company has agreed to issue..PharmaDrug Brings On Advisor to Maximize Shareholder Value With Its Underlying Assets
Toronto, Ontario--(Newsfile Corp. - May 23, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is announcing that it has appointed David Posner to its Advisory Committee and as a consultant with a mandate for strategic initiatives and corporate restructuring. Daniel Cohen, Chairman and CEO of PharmaDrug commented, "We are extremely excited to bring David Posner on as an advisor. David has a long history of founding companies in the cannabis, psychedelic
Read more news
Top Holding Companies & Conglomerates Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Pharmadrug
Sign Up For FreeTo access detailed company insights
PharmaDrug owns 51% of Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthi... Read More
